

115TH CONGRESS
2D SESSION

H. R. 6958

To provide for a study and report on the feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on the average prices for such drugs in the member-states of the Organization for Economic Cooperation and Development.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 27, 2018

Mr. FRANCIS ROONEY of Florida (for himself and Mr. WELCH) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To provide for a study and report on the feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on the average prices for such drugs in the member-states of the Organization for Economic Cooperation and Development.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Drug Price Trans-
5 parency Act”.

1 **SEC. 2. STUDY AND REPORT ON FEASIBILITY OF BASING**
2 **REIMBURSEMENT RATES FOR MEDICARE**
3 **PART B DRUGS AND COVERED PART D DRUGS**
4 **ON AVERAGE PRICES FOR SUCH DRUGS IN**
5 **OECD MEMBER STATES.**

6 From amounts otherwise made available to the Sec-
7 retary of Health and Human Services, the Secretary shall
8 use not to exceed \$100,000 of such amounts to, not later
9 than 90 days after the date of the enactment of this Act,
10 conduct a study, and submit to Congress a report, on the
11 feasibility of—

12 (1) basing reimbursement rates under part B of
13 the Medicare program under title XVIII of the So-
14 cial Security Act for prescription drugs for which
15 coverage is provided under part B of the Medicare
16 program on the average price of such drugs in the
17 member-states of the Organization for Economic Co-
18 operation and Development; and

19 (2) basing payment rates under prescription
20 drug plans under part D of such title (and under
21 MA–PD plans under part C of such title) for cov-
22 ered part D drugs (as defined in section 1860D–2(e)
23 of such Act (42 U.S.C. 1395w–102(e))) on the aver-
24 age price of such drugs in such member-states.

○